As a new method, immunotherapy which is targeting programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) plays a more and more important role in the treatment of malignant tumors. Immunotherapy is more effective than traditional chemotherapy. However, there are also many adverse events during the application of immunocheckpoint inhibitors targeting PD-1/PD-L1, and the incidence rate of these adverse events among different drugs is different. Because the molecular structure of these drugs is an important indicator to distinguish them, this paper will analyze the correlation between molecular structure and adverse events of PD-1/PD-L1 immunocheckpoint inhibitors through reviewing some meta-analyses and retrospective analyses from the perspective of different structures.
【中文题目：解析PD-1/PD-L1抑制剂分子结构差异 与不良反应的相关性】 【中文摘要：针对程序性死亡受体1（programmed cell death protein 1, PD-1）及程序性死亡配体1（programmed cell death ligand 1, PD-L1）的免疫治疗作为一种新兴的方法在恶性肿瘤的治疗中起到越来越大的作用，相较于传统的化学治疗体现出更好的疗效。然而在应用针对PD-1/PD-L1的免疫检查点抑制剂的过程中也出现了许多不良反应，并且这些不良反应在不同药物中的发生率也不完全相同。由于区分不同药物的一个重要指标是它们的分子结构，故本文将从不同PD-1/PD-L1免疫检查点抑制剂的结构出发，通过综述不良反应的meta分析以及回顾性研究的结果解析分子结构与不良反应发生情况之间的相关性。】 【中文关键词：程序性死亡受体1；程序性死亡配体1；结构；不良反应】.
Keywords: Adverse events; Programmed cell death ligand 1; Programmed cell death protein 1; Structure.